Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
32.24
+0.10 (0.31%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Veracyte Revenue
In the year 2024, Veracyte had annual revenue of $445.76M with 23.46% growth. Veracyte had revenue of $118.63M in the quarter ending December 31, 2024, with 20.81% growth.
Revenue (ttm)
$445.76M
Revenue Growth
+23.46%
P/S Ratio
5.53
Revenue / Employee
$540,976
Employees
824
Market Cap
2.51B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
VCYT News
- 14 hours ago - Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer - Business Wire
- 3 days ago - Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting - Business Wire
- 4 days ago - Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release - Business Wire
- 4 weeks ago - New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - Business Wire
- 5 weeks ago - Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - Business Wire
- 2 months ago - Solid Growth, Soft Outlook: Why I'm Holding On Veracyte - Seeking Alpha
- 2 months ago - Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive - Benzinga
- 2 months ago - Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript - Seeking Alpha